beta(2)-adrenoceptor polymorphisms and obstructive airway diseases: Important issues of study design

Yang, Ian A., Ng, Taria, Molenaar, Peter and Fong, Kwun M. (2007) beta(2)-adrenoceptor polymorphisms and obstructive airway diseases: Important issues of study design. Clinical And Experimental Pharmacology and Physiology, 34 10: 1029-1036.


Author Yang, Ian A.
Ng, Taria
Molenaar, Peter
Fong, Kwun M.
Title beta(2)-adrenoceptor polymorphisms and obstructive airway diseases: Important issues of study design
Formatted title β2-adrenoceptor polymorphisms and obstructive airway diseases: Important issues of study design
Journal name Clinical And Experimental Pharmacology and Physiology   Check publisher's open access policy
ISSN 0305-1870
1440-1681
Publication date 2007-10
Sub-type Article (original research)
DOI 10.1111/j.1440-1681.2007.04731.x
Volume 34
Issue 10
Start page 1029
End page 1036
Total pages 8
Place of publication Richmond, Australia
Publisher Wiley-Blackwell
Collection year 2008
Language eng
Subject C1
321201 Environmental and Occupational Health and Safety
730208 Occupational health (excl. economic development aspects)
Abstract Asthma and chronic obstructive pulmonary disease (COPD) are chronic airway diseases characterized by airflow obstruction. The beta(2)-adrenoceptor mediates bronchodilatation in response to exogenous and endogenous beta-adrenoceptor agonists. Single nucleotide polymorphisms in the beta(2)-adrenoceptor gene (ADRB2) cause amino acid changes (e.g. Arg16Gly, Gln27Glu) that potentially alter receptor function. Recently, a large cohort study found no association between asthma susceptibility and beta(2)-adrenoceptor polymorphisms. In contrast, asthma phenotypes, such as asthma severity and bronchial hyperresponsiveness, have been associated with beta(2)-adrenoceptor polymorphisms. Of importance to asthma management, coding region polymorphisms may alter the response to short-acting and long-acting beta-adrenoceptor agonists, which are commonly prescribed asthma treatments. Optimizing study design would enhance the robustness of genetic association studies of ADRB2 polymorphisms in airway diseases. Characteristics of high-quality studies include suitable study design and subject selection, optimal study of polymorphisms and haplotypes, disease outcomes of relevance, adequate sample size, adjustment for confounding factors, supportive functional data and appropriate analysis, interpretation and replication. Enhancing these study design factors will provide high-quality evidence regarding the biological and clinical importance of beta(2)-adrenoceptor pharmacogenomics in asthma and COPD.
Keyword Adrenergic
Beta(2)-adrenoceptor/genetics
Asthma
Genetic
Polymorphism
Receptors
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Access Statistics: 84 Abstract Views  -  Detailed Statistics
Created: Mon, 18 Feb 2008, 14:49:40 EST